These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 3779125)

  • 1. [Advanced cancer of the prostate: chemotherapy].
    Garcia-Giralt E; Palangie T; Dorval T; Jouve M; Pouillart P
    Bull Cancer; 1986; 73(1):68-73. PubMed ID: 3779125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful treatment of poor prognostic patients with advanced prostatic carcinoma with the association of diethylstilbestrol and cyclophosphamide.
    Germá Lluch JR; Marcuello Gaspar E; de Andrés Basauri L; López Pousa A; López López JJ
    Rev Esp Oncol; 1982; 29(2):317-24. PubMed ID: 7188232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Chemotherapy of prostatic cancer].
    Portnoĭ AS
    Vopr Onkol; 1985; 31(9):3-12. PubMed ID: 2931901
    [No Abstract]   [Full Text] [Related]  

  • 4. Randomized trial of combination chemotherapy in hormone-resistant metastatic prostate carcinoma.
    Page JP; Levi JA; Woods RL; Tattersall MN; Fox RM; Coates AS
    Cancer Treat Rep; 1985 Jan; 69(1):105-7. PubMed ID: 3881176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment for hormone-refractory or relapsing prostatic cancer].
    Hirao Y; Ozono S; Okajima E
    Gan To Kagaku Ryoho; 1996 Mar; 23(4):418-26. PubMed ID: 8678492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Metastatic breast cancer: controlled trial of chemotherapy with and without hormones].
    Jouve M; Palangie T; Garcia-Giralt E; Bretaudeau B; Magdelenat H; Asselain B; Pouillart P
    Bull Cancer; 1984; 71(5):432-41. PubMed ID: 6395920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapy of hormonally unresponsive prostatic carcinoma.
    deKernion JB; Lindner A
    Urol Clin North Am; 1984 May; 11(2):319-26. PubMed ID: 6233779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of the association of doxorubicin, 5 FU and cis platinum in hormonally unresponsive metastatic carcinoma of the prostate.
    Droz JP; Fargeot P; Laplaige P; Moran-Ribon A; Piot G
    Prog Clin Biol Res; 1987; 243B():235-42. PubMed ID: 3659022
    [No Abstract]   [Full Text] [Related]  

  • 9. Treatment of hormone-resistant metastatic carcinoma of the prostate with 5-FU, doxorubicin, and mitomycin (FAM'): a preliminary report.
    Kasimis BS; Moran EM; Miller JB; Forbes KA; Kaneshiro CA; Poblet MT; Williams JL
    Cancer Treat Rep; 1983 Oct; 67(10):937-9. PubMed ID: 6688755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival after cytotoxic chemotherapy in patients with advanced hormone-resistant prostate cancer: a phase II study.
    Stathopoulos GP; Koutantos J; Vaslamatzis MM; Athanasiadis A; Papadopoulos G; Labrodimou G; Stathopoulos J; Rigatos S
    Oncol Rep; 2009 Aug; 22(2):345-8. PubMed ID: 19578775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Combined hormone and chemotherapy for the patients with advanced prostate cancer].
    Uekado Y; Hirano A; Inagaki T; Hiroi A; Watanabe T
    Gan To Kagaku Ryoho; 1995 Jul; 22(8):1041-5. PubMed ID: 7611755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of oral cyclophosphamide, prednisone, and diethylstilbestrol for androgen-independent prostate carcinoma.
    Hellerstedt B; Pienta KJ; Redman BG; Esper P; Dunn R; Fardig J; Olson K; Smith DC
    Cancer; 2003 Oct; 98(8):1603-10. PubMed ID: 14534875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pilot study of AFL-T (doxorubicin, 5-fluorouracil, leucovorin, and tamoxifen) combination chemotherapy for hormone-refractory prostate cancer.
    Lin CC; Hsu CH; Chen J; Tsai TC; Cheng AL; Pu YS
    Anticancer Res; 2001; 21(2B):1385-90. PubMed ID: 11396219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The case for early combined hormonal and cytostatic treatment for metastatic prostatic carcinoma.
    Servadio C
    Prog Clin Biol Res; 1987; 243B():449-53. PubMed ID: 3659039
    [No Abstract]   [Full Text] [Related]  

  • 15. Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer.
    Pummer K; Lehnert M; Stettner H; Hubmer G
    Eur Urol; 1997; 32 Suppl 3():81-5. PubMed ID: 9267791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Intraarterial chemotherapy via reservoir system for far-advanced bladder and prostate cancer].
    Takahashi Y; Yamamoto N; Deguchi T; Kuriyama M; Yoh M; Yasuda M; Nakano M; Kawada Y; Takeuchi T; Shinoda I
    Gan To Kagaku Ryoho; 1998 Jul; 25(9):1310-3. PubMed ID: 9703815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapy of hormone-resistant carcinoma of the prostate: 4-epi-rubicin weekly v.s. DMF monthly.
    Burk K; Sropp C; Schultze-Seemann W; de Riese W
    Prog Clin Biol Res; 1987; 243B():243-6. PubMed ID: 3116556
    [No Abstract]   [Full Text] [Related]  

  • 18. [Effect of UFT on treatment of urological cancer--effect of UFT on treatment of invasive bladder cancer and advanced prostate cancer. Ibaraki Urological Cancer Chemotherapy Study Group].
    Uchida K; Takeshima H; Kikuchi K; Shimazui T; Miyanaga N; Kawai K; Akaza H; Tsuchiya A; Noguchi R; Hattori K; Manabe F; Matsuki K; Suzuki R; Ishikawa S; Kondo F; Kobayashi T; Koiso K
    Gan To Kagaku Ryoho; 1998 Jul; 25(8):1179-87. PubMed ID: 9679581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hormone chemotherapy for newly diagnosed patients with metastatic prostate cancer.
    Kubota Y; Nakada T; Suzuki Y; Iizima Y; Adachi Y; Hashimoto T
    Int Urol Nephrol; 1993; 25(5):469-74. PubMed ID: 8270375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Chemotherapy of advanced prostate cancer].
    Hofmann W; Langkopf B
    Z Urol Nephrol; 1986 Jan; 79(1):33-9. PubMed ID: 2938361
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.